The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10917 malaria professionals are enjoying the free benefits of MalariaWorld today

antimalarial vaccine

The molecular basis for peptide-based antimalarial vaccine development targeting erythrocyte invasion by P. falciparum

December 15, 2020 - 14:15 -- Open Access
Aza-Conde J, Reyes C, Suárez CF, Patarroyo MA, Patarroyo ME
Biochem Biophys Res Commun. 2020 Dec 10;534:86-93

This work describes a methodology for developing a minimal, subunit-based, multi-epitope, multi-stage, chemically-synthesised, anti-Plasmodium falciparum malaria vaccine. Some modified high activity binding peptides (mHABPs) derived from functionally relevant P. falciparum MSP, RH5 and AMA-1 conserved amino acid regions (cHABPs) for parasite binding to and invasion of red blood cells (RBC) were selected.

Pre-Erythrocytic Vaccines against Malaria

July 29, 2020 - 10:28 -- Open Access
Marques-da-Silva C, Peissig K, Kurup SP
Vaccines (Basel). 2020 Jul 21;8(3):E400

Malaria, caused by the protozoan Plasmodium, is a devastating disease with over 200 million new cases reported globally every year. Although immunization is arguably the best strategy to eliminate malaria, despite decades of research in this area we do not have an effective, clinically approved antimalarial vaccine.

A Novel Chemically Differentiated Mouse Embryonic Stem Cell-Based Model to Study Liver Stages of Plasmodium berghei

May 25, 2020 - 07:51 -- Open Access
Tripathi J, Segeritz CP, Griffiths G, Bushell W, Vallier L, Skarnes WC, Mota MM, Billker O
Stem Cell Reports. 2020 May 20:S2213-6711(20)30150-8

Asymptomatic and obligatory liver stage (LS) infection of Plasmodium parasites presents an attractive target for antimalarial vaccine and drug development. Lack of robust cellular models to study LS infection has hindered the discovery and validation of host genes essential for intrahepatic parasite development.

Subscribe to RSS - antimalarial vaccine